S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NYSE:USNA

USANA Health Sciences (USNA) Stock Price, News & Analysis

$48.27
+0.74 (+1.56%)
(As of 03/27/2024 ET)
Today's Range
$47.78
$48.61
50-Day Range
$46.47
$52.36
52-Week Range
$44.01
$69.60
Volume
61,548 shs
Average Volume
101,139 shs
Market Capitalization
$928.71 million
P/E Ratio
14.63
Dividend Yield
N/A
Price Target
$48.00

USANA Health Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
0.6% Downside
$48.00 Price Target
Short Interest
Healthy
2.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.38mentions of USANA Health Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth
14.65%
From $2.73 to $3.13 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.42 out of 5 stars

Medical Sector

340th out of 939 stocks

Medicinals & Botanicals Industry

2nd out of 11 stocks

USNA stock logo

About USANA Health Sciences Stock (NYSE:USNA)

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

USNA Stock Price History

USNA Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
USNA Apr 2024 45.000 put
Kevin Guest Says Leap Forward on Leap Day
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
Jim Simons Adjusts Position in Usana Health Sciences Inc
USANA Health Sciences Q4 Income Climbs, Beats estimates
USANA (NYSE:USNA) Q4 Sales Beat Estimates
Kevin Guest Names 2024 the Year of Connection
See More Headlines
Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
3/28/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
Personal Products
CUSIP
90328M10
Employees
1,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.00
High Stock Price Target
$48.00
Low Stock Price Target
$48.00
Potential Upside/Downside
-0.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$63.79 million
Pretax Margin
11.12%

Debt

Sales & Book Value

Annual Sales
$921.01 million
Cash Flow
$4.47 per share
Book Value
$25.99 per share

Miscellaneous

Free Float
19,178,000
Market Cap
$928.71 million
Optionable
Optionable
Beta
0.90
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

USNA Stock Analysis - Frequently Asked Questions

Should I buy or sell USANA Health Sciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" USNA shares.
View USNA analyst ratings
or view top-rated stocks.

What is USANA Health Sciences' stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for USANA Health Sciences' shares. Their USNA share price targets range from $48.00 to $48.00. On average, they anticipate the company's stock price to reach $48.00 in the next twelve months. This suggests that the stock has a possible downside of 0.6%.
View analysts price targets for USNA
or view top-rated stocks among Wall Street analysts.

How have USNA shares performed in 2024?

USANA Health Sciences' stock was trading at $53.60 at the beginning of the year. Since then, USNA stock has decreased by 9.9% and is now trading at $48.27.
View the best growth stocks for 2024 here
.

Are investors shorting USANA Health Sciences?

USANA Health Sciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 255,100 shares, an increase of 49.4% from the February 29th total of 170,700 shares. Based on an average trading volume of 76,200 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.3% of the company's stock are sold short.
View USANA Health Sciences' Short Interest
.

When is USANA Health Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our USNA earnings forecast
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its earnings results on Tuesday, February, 6th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.52 by $0.35. The firm earned $221.08 million during the quarter, compared to analysts' expectations of $206.70 million. USANA Health Sciences had a net margin of 6.93% and a trailing twelve-month return on equity of 13.49%.

What ETFs hold USANA Health Sciences' stock?
What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 2.400-3.000 for the period, compared to the consensus estimate of 2.940. The company issued revenue guidance of $850.0 million-$920.0 million, compared to the consensus revenue estimate of $912.3 million.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.27%), Vanguard Group Inc. (8.20%), Pzena Investment Management LLC (3.98%), Dimensional Fund Advisors LP (3.54%), Pacer Advisors Inc. (1.76%) and Charles Schwab Investment Management Inc. (1.16%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Paul A Jones, Robert A Sinnott, Robert A Sinnott, Robert Auciaux, Walter Noot and Xia Ding.
View institutional ownership trends
.

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:USNA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners